Stem cell-based therapies represent a potential pathway for a new era of 21st century regenerative medicine. In support of this new form of treatment, a global multibillion-dollar research endeavor is currently underway in an effort to establish a scie…
Technology has promoted global health. Yet advancing technology has also allowed physicians and trainees to cheat, and inappropriate experimentation with medical technology has resulted in study patient deaths. Further, journal editors have not made significant inroads in employing technology to identify dishonesty. Unfortunately, this continues to be strongly within the culture of the profession. Due to corruption of medicine, global health promotion will be severely retarded by falsified and suspect data that lower-and-middle income countries cannot afford to reproducethemselves and must rely upon for clinical decisionmaking. Further, clinical environments that facilitate dishonesty will result in poorer patient care. In addition, emerging markets rely on research to produce advanced therapeutics such as biosimilars that will be used by developed and developing economies, compounding the potential risks of dishonesty globally. By employing relevant antiplagiarism technology and accessing funding sources for all parties including authors, reviewers, and journal editors; “honesty” accreditation that includes mandated participation by journals; and external audits and whistleblowing of dishonesty, medical culture globally can move toward honesty and take advantage of technological evolution to promote global health.
This is the introduction piece for the 9th San Diego Health Policy Conference, with papers by Tom Kubic, John Theriault, Tim Mackey, Jim Balcius, and Bryan A. Liang.
Human Genome Science (HGS) aspired to dominate the emergent field of genomics by discovering expressed gene sequences and developing therapeutic and diagnostic products based on proprietary genes. While HGS’ accomplishments fell short of their own lofty expectations, by the time HGS was acquired by GlaxoSmithKline, the company had extensive intellectual property and had launched a product with >$1 billion market potential. Nevertheless, HGS’ acquisition price was less than the total capital investments in the company. This work examines HGS’ history and accomplishments in the context of the business plan described by the company at their IPO. We focus specifically on the company’s valuation over time, which was highly correlated with general market indices, but negatively correlated with metrics of technical or clinical progress. The history of HGS points to the challenge of accounting for the value created by a science-based business plan. Earnings-based metrics, present value calculations, and “fair value” assessments did not account for HGS’ progress in executing their stated business plan. This work highlights the critical need for accounting practices that credit value to the progress of translational science and enable investors to profit from such investments.
The recombinant drug industry is growing at almost 20% rate in India. The long term growth of this sector depends upon the innovation as well as competition and market. The structure, conduct and performance of firms in market plays a very important ro…
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 20 | |||||||||||||||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
ADVICOR | Abbvie | lovastatin; niacin | Sep 20, 2013 | ||||||
NIASPAN | Abbvie | niacin | Sep 20, 2013 | ||||||
NIASPAN TITRATION STARTER PACK | Abbvie | niacin | Sep 20, 2013 | ||||||
SIMCOR | Abbvie | niacin; simvastatin | Sep 20, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
 Which Companies Face the Most Patent |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 21 | |||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
ZYFLO CR | Cornerstone Therap | zileuton | Sep 21, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
Which Companies Face the Most Patent |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 16 | |||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
CANCIDAS | Merck | caspofungin acetate | Sep 16, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
 Which |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 17 | |||||||||||||||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
AVODART | Glaxosmithkline | dutasteride | Sep 17, 2013 | ||||||
DIASTAT | Valeant | diazepam | Sep 17, 2013 | ||||||
DIASTAT ACUDIAL | Valeant | diazepam | Sep 17, 2013 | ||||||
JALYN | Glaxosmithkline | dutasteride; tamsulosin hydrochloride | Sep 17, 2013 | ||||||
*Drugs may be covered by multiple | |||||||||
DrugPatentWatch Infographics |
Which |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations
This newsletter is
a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents
Drug Patent Expirations for September 20 | |||||||||||||||||||||||||||||||||
| Tradename | Applicant | Generic Name | Patent Expiration | ||||||
|---|---|---|---|---|---|---|---|---|---|
ADVICOR | Abbvie | lovastatin; niacin | Sep 20, 2013 | ||||||
NIASPAN | Abbvie | niacin | Sep 20, 2013 | ||||||
NIASPAN TITRATION STARTER PACK | Abbvie | niacin | Sep 20, 2013 | ||||||
SIMCOR | Abbvie | niacin; simvastatin | Sep 20, 2013 | ||||||
*Drugs may be | |||||||||
DrugPatentWatch Infographics |
Which |
| More infographics » |
DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.
